NCT02310399

Brief Summary

This study is a feasibility study of the Nucleus 24 ABI in children without NF2. It will be conducted as a repeated-measures, single subject experiment in order to accommodate the known variability in cochlear implant clinical results. Data obtained in the course of this study will be compared with the existing published outcome data from children with normal hearing and with cochlear implants (CIs). These comparisons may provide additional useful information about the progress of ABI subjects' performance over time. Also, this may allow the results of the current study to be utilized to design future pivotal studies of the device in the pediatric population.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
49mo left

Started May 2014

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress75%
May 2014May 2030

Study Start

First participant enrolled

May 1, 2014

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

November 28, 2014

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 8, 2014

Completed
15.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2030

Last Updated

October 30, 2025

Status Verified

October 1, 2025

Enrollment Period

16 years

First QC Date

November 28, 2014

Last Update Submit

October 29, 2025

Conditions

Keywords

Auditory Brainstem ImplantDeafnessHearing LossABI

Outcome Measures

Primary Outcomes (1)

  • ABI Device Complications

    Study participants will be monitored on a case-by-case basis for ongoing or unanticipated medical complications. Adverse events will be tracked on a case-by-case basis and recorded at the time of occurrence and followed up at resolution. Any adverse events will be reported to the NYUSOM IRB. Should there be concern for the safety of the subjects because of their participation in the study by the investigators or the IRB, the study would be halted at least temporarily and a detailed discussion with the investigators and the IRB would be undertaken.

    5 Years from date of surgery

Secondary Outcomes (1)

  • Audiologic Performance with ABI (Hearing, Speech and Language Assessments)

    36 months from date of surgery

Study Arms (2)

Pre-lingual Deafness

EXPERIMENTAL

Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in prelingiustically deaf children ages 18 months - 5 years

Device: Nucleus ABI541 Auditory Brainstem Implant

Post-Lingual Deafness

EXPERIMENTAL

Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in postlinguistically deaf children \< 21 years of age

Device: Nucleus ABI541 Auditory Brainstem Implant

Interventions

Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device

Post-Lingual DeafnessPre-lingual Deafness

Eligibility Criteria

Age18 Months - 21 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Group 1: Prelinguistic hearing loss (birth-5 years; age at implantation of ABI 18 months-5 years)
  • Pre-linguistic hearing loss (birth-5 yrs.; age at ABI 18 months-5yrs) with both:
  • MRI +/- CT evidence of one of the following:
  • Cochlear nerve deficiency
  • Cochlear aplasia or severe hypoplasia
  • Severe inner ear malformation
  • Post-meningitis ossification
  • When a cochlea is present or patent, lack of significant benefit from CI despite consistent use (\>6 mo.)
  • No or limited speech perception ability (limited to pattern perception on closed set testing materials using the CI)
  • Lack of progress in auditory skills development
  • Group 2: Post-linguistic hearing loss (\<21 yrs. of age)
  • Post-linguistic hearing loss (\<21 yrs. of age) with:
  • Loss or lack of benefit from appropriate CI without the possibility for revision or contralateral implantation. Examples might include:
  • Post-meningitis ossification
  • Bilateral temporal bone fractures with cochlear nerve avulsion
  • +13 more criteria

You may not qualify if:

  • For both Groups 1 and 2:
  • Pre- or post-linguistic child currently making significant progress with CI Even for the very young children (18 months of age with 6 months of use), nearly all children with a good auditory signal from their CI will show evidence of improvement in these metrics over time.
  • MRI evidence of one of the following:
  • normal cochlea and cochlear nerves or NF2
  • brainstem or cortical anomaly that makes implantation unfeasible
  • Clear surgical reason for poor CI performance that can be remediated with revision CI or contralateral surgery rather than ABI.
  • Intractable seizures or progressive, deteriorating neurological disorder
  • Patients with evidence of Chiari malformation, hydrocephalus, spina bifid a
  • Patients with any foreseeable need for a future MRI scan
  • Unable to participate in behavioral testing and mapping with their CI. If this appears to be an age effect, ABI will be delayed until we can be assured that the child will be able to participate, as reliable objective measures of mapping are currently not available for mapping these devices.
  • Unable to tolerate general anesthesia (cardiac, pulmonary, bleeding diathesis, etc.).
  • Need for brainstem irradiation
  • Unrealistic expectations on the part of the subject/family regarding the possible benefits, risks and limitations inherent to the procedure and ABI device.
  • Unwilling to sign the informed consent.
  • Unwilling to make necessary follow-up appointments.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NYU Cochlear Implant Center

New York, New York, 10016, United States

RECRUITING

Related Publications (6)

  • Colletti V, Shannon R, Carner M, Veronese S, Colletti L. Outcomes in nontumor adults fitted with the auditory brainstem implant: 10 years' experience. Otol Neurotol. 2009 Aug;30(5):614-8. doi: 10.1097/MAO.0b013e3181a864f2.

    PMID: 19546832BACKGROUND
  • Colletti L, Zoccante L. Nonverbal cognitive abilities and auditory performance in children fitted with auditory brainstem implants: preliminary report. Laryngoscope. 2008 Aug;118(8):1443-8. doi: 10.1097/MLG.0b013e318173a011.

    PMID: 18496153BACKGROUND
  • Sennaroglu L, Ziyal I, Atas A, Sennaroglu G, Yucel E, Sevinc S, Ekin MC, Sarac S, Atay G, Ozgen B, Ozcan OE, Belgin E, Colletti V, Turan E. Preliminary results of auditory brainstem implantation in prelingually deaf children with inner ear malformations including severe stenosis of the cochlear aperture and aplasia of the cochlear nerve. Otol Neurotol. 2009 Sep;30(6):708-15. doi: 10.1097/MAO.0b013e3181b07d41.

    PMID: 19704357BACKGROUND
  • Sennaroglu L, Ziyal I. Auditory brainstem implantation. Auris Nasus Larynx. 2012 Oct;39(5):439-50. doi: 10.1016/j.anl.2011.10.013. Epub 2011 Dec 22.

    PMID: 22196501BACKGROUND
  • Colletti L, Shannon RV, Colletti V. The development of auditory perception in children after auditory brainstem implantation. Audiol Neurootol. 2014;19(6):386-94. doi: 10.1159/000363684. Epub 2014 Nov 4.

    PMID: 25377987BACKGROUND
  • Colletti L, Wilkinson EP, Colletti V. Auditory brainstem implantation after unsuccessful cochlear implantation of children with clinical diagnosis of cochlear nerve deficiency. Ann Otol Rhinol Laryngol. 2013 Oct;122(10):605-12.

    PMID: 24294682BACKGROUND

Related Links

MeSH Terms

Conditions

Hearing LossDeafness

Condition Hierarchy (Ancestors)

Hearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • John T. Roland, Jr., MD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 28, 2014

First Posted

December 8, 2014

Study Start

May 1, 2014

Primary Completion (Estimated)

May 1, 2030

Study Completion (Estimated)

May 1, 2030

Last Updated

October 30, 2025

Record last verified: 2025-10

Locations